On October 24, 2019 Pfenex Inc. (NYSE American: PFNX), a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology to develop and improve protein therapies for unmet patient needs, reported that it will report its financial results for the third quarter 2019, after the market close on Thursday, November 7, 2019 (Press release, Pfenex, OCT 24, 2019, View Source [SID1234542492]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company will host a conference call to discuss financial results and general business updates at 4:30 PM Eastern Time on Thursday, November 7, 2019.

Conference Call & Webcast
Thursday, November 7th @ 4:30pm Eastern Time/1:30pm Pacific Time
Domestic: 866-376-8058
International: 412-542-4131
Webcast: View Source

Replays available through November 14th:
Domestic: 877-344-7529
International: 412-317-0088
Replay Access Code: 10136405